The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop… Read More
Tariq E. Khoyratty DPhil, Computational Biologist, Aigenpulse, and Satnam Surae PhD, Chief Product Officer, Aigenpulse, discuss the challenge of the large volume of data generated and how automation/AI/ML can help to manage this. As pharmaceutical companies expand their research and development (R&D) efforts to meet the growing global demand for new drugs,… Read More
Rhythm AI, a UK company focused on the treatment of Atrial Fibrillation (AF) has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with its multi-centre ROCSTAR clinical trial. This program will assess the company’s STAR Mapping System as a potential treatment for persistent AF. Read More
Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. Pharma invests in powerful software technologies with the promise of increased efficiencies, but ultimately, if the interfaces are unintuitive and more… Read More
As a consequence of the coronavirus pandemic, 41% of global clinical trials in fields other than COVID-19 (c.4,5001) have been delayed or put on permanent hold. Looking ahead, 74% of life science organisations say that COVID-19 will continue to compromise their ability to deliver on clinical trial objectives for the… Read More
Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More
Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More
The multi-year process of drug discovery and development creates huge silos of data and information. Extracting and combining information can be a significant overhead, resulting in potential for delay and error. Iperion’s Duncan van Rijsbergen provides practical recommendations to help companies create high quality, consistent data that may be shared… Read More
Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially? More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug… Read More
Dr. Steve Arlington and Dr. Nick Lynch, The Pistoia Alliance, provide insight into pre-competitive collaboration and data sharing as we thinks about R&D beyond the pandemic At the Pistoia Alliance, our mission is to encourage collaboration across the life sciences ecosystem. We believe that scientific advances and breakthroughs cannot be… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More
THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More
By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More
The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More